CABALETTA BIO INC Share Price Today: Live Updates & Key Insights

CABALETTA BIO INC share price today is $2.74, up -1.1%. The stock opened at $2.7 against the previous close of $2.72, with an intraday high of $2.73 and low of $2.63.

CABALETTA BIO INC Share Price Chart

CABALETTA BIO INC

us-stock
To Invest in {{usstockname}}
us-stock

CABALETTA BIO INC Share Price Performance

$2.74 -0.011(-1.1%) CABA at 27 Jul 2026 02:20 PM Biotechnology
Lowest Today 2.63
Highest Today 2.73
Today’s Open 2.7
Prev. Close 2.72
52 Week High 4.23
52 Week Low 1.26
Day’s Range: Low 2.63 High 2.73
52-Week Range: Low 1.26 High 4.23
1 day return -
1 Week return -2.0
1 month return -11.38
3 month return -8.2
6 month return -8.67
1 year return +58.4
3 year return -77.82
5 year return -64.8
10 year return -

CABALETTA BIO INC Institutional Holdings

T. Rowe Price Investment Management,Inc. 9.95

Bain Capital Life Sciences Investors, LLC 8.69

Jennison Associates LLC 8.06

Adage Capital Partners Gp LLC 7.93

T. Rowe Price Small-Cap Value 7.07

Millennium Management LLC 5.30

Cormorant Asset Management, LLC 4.94

State Street® SPDR® S&P® Biotech ETF 4.70

Vanguard Total Stock Mkt Idx Inv 4.68

T. Rowe Price U.S. SC Value Eq Tr-D 4.65

Jennison Health Sciences Equity 4.46

PGIM Jennison Health Sciences Z 4.46

Vanguard Group Inc 3.97

Vanguard Capital Management, LLC 3.62

iShares Russell 2000 ETF 2.64

Jennison SMid Cap Core Equity 2.42

PGIM Jennison Small Company A 2.42

Two Sigma Investments LLC 2.24

BlackRock Inc 2.13

Marshall Wace Asset Management Ltd 1.96

Renaissance Technologies Corp 1.83

Qube Research & Technologies 1.74

Vanguard Institutional Extnd Mkt Idx Tr 1.69

T. Rowe Price Health Sciences 1.61

Franklin Biotechnology Discv A(acc)USD 1.38

Morgan Stanley - Brokerage Accounts 1.26

T. Rowe Price Small-Cap Stock 1.25

Opaleye Management Inc 1.24

T. Rowe Price New Horizons 1.23

JENNISON SMALL/MID CAP EQUITY 3 1.16

Woodline Partners LP 1.12

Geode Capital Management, LLC 1.02

SUPERSTRING CAPITAL MANAGEMENT LP 0.96

iShares Biotechnology ETF 0.91

T. Rowe Price US Smlr Coms Eq A 0.81

Ikarian Capital, LLC 0.81

Franklin Biotechnology Discovery A 0.79

The Goldman Sachs Group Inc 0.70

International Biotechnology Ord 0.68

T. Rowe Price Instl Small-Cap Stock 0.67

CABALETTA BIO INC Market Status

Strong Buy: 8

Buy: 2

Hold: 2

Sell: 0

Strong Sell: 0

CABALETTA BIO INC Fundamentals

Market Cap 443.51 M

PB Ratio 4.3406

PE Ratio 0.0

Enterprise Value 358.22 M

Total Assets 165.08 M

Volume 1662378

CABALETTA BIO INC Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:-1426000 -1.4M, FY22:null 0.0M, FY21:null 0.0M, FY20:0 0.0M, FY19:null 0.0M

Annual Net worth FY23:-67675000 -67.7M, FY22:-51811000 -51.8M, FY21:-45532000 -45.5M, FY20:-32491000 -32.5M, FY19:-15099000 -15.1M

Quarterly Revenue Q1/2026:0 0.0M, Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M

Quarterly Profit Q1/2026:-337000 -0.3M, Q3/2025:-345000 -0.3M, Q2/2025:-468000 -0.5M, Q1/2025:-485000 -0.5M, Q3/2024:null 0.0M

Quarterly Net worth Q1/2026:-43515000 -43.5M, Q3/2025:-44866000 -44.9M, Q2/2025:-45128000 -45.1M, Q1/2025:-35943000 -35.9M, Q3/2024:-30629000 -30.6M

About CABALETTA BIO INC & investment objective

Company Information Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Organisation Biotechnology

Employees 156

Industry Biotechnology

CEO Dr. Steven A. Nichtberger M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

CABALETTA BIO INC FAQs

What is the share price of CABALETTA BIO INC today?

The current share price of CABALETTA BIO INC is $2.74.

Can I buy CABALETTA BIO INC shares in India?

Yes, Indian investors can buy CABALETTA BIO INC shares by opening an international trading and demat account with Motilal Oswal.

How to buy CABALETTA BIO INC shares in India?

You can easily invest in CABALETTA BIO INC shares from India by:

Can I buy fractional shares of CABALETTA BIO INC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of CABALETTA BIO INC?

CABALETTA BIO INC has a market cap of $443.51 M.

In which sector does CABALETTA BIO INC belong?

CABALETTA BIO INC operates in the Biotechnology sector.

What documents are required to invest in CABALETTA BIO INC stocks?

To invest, you typically need:

What is the PE and PB ratio of CABALETTA BIO INC?

The PE ratio of CABALETTA BIO INC is N/A and the PB ratio is 4.34.